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by HPLC. SW1353 and primary human chondrocytes obtained after total
knee replacement surgery from patients with osteoarthritis (OA) were
cultured in DMEM with 10% FCS. Cytotoxicity of different CSE concentra-
tions was examined using MTT and BrdU assays. Quantitative real-time
RT-PCR (RT-qPCR) was used to evaluate the effects of CSE on mRNA
levels of interleukin-1-beta (IL-1β), tumor necrosis factor-alpha (TNF-α), in-
ducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and matrix
metalloproteinase-3 (MMP-3). The nitric oxide (NO) production was mea-
sured using Griess assay. The gelatinolytic activity of MMPs was determined
by zymography. Transient transfection and luciferase assay was performed
to study CSE action on NF-kappaB signalling.
Results: Dose-response experiments revealed that up to 20 μg/ml CSE did
not impair viability of chondrocytes. CSE treatments (5-20 μg/ml) signif-
icantly suppressed the up-regulation of proinﬂammatory cytokine mRNA
(IL-1β and TNF-α) in response to IL-1β (10 ng/ml) stimulation in SW1353
and primary chondrocytes (p<0.05). At the same concentrations, CSE in-
hibited the IL-1β induced up-regulation of MMP3 mRNA and gelatinolytic
activity of MMPs in a dose-dependent manner. A signiﬁcant inhibition of
NO production and iNOS mRNA expression was also observed in IL-1β
stimulated primary chondrocytes pretreated with CSE (p<0.05). Cotrans-
fections of the COX-2 promoter luciferase reporter plasmid together with
p50 and p65 expression vectors enhanced the COX-2 promoter activity
3.4-fold in SW1353 cells. This p50/p65-mediated transactivation of the
COX-2 promoter was dose-dependently down-regulated to basal levels by
CSE.
Conclusions: These results indicate that CSE possesses potent anti-
inﬂammatory activity in osteoarthritic chondrocytes. In particular, its
action might involve the inhibition of NO production via iNOS downreg-
ulation as well as the inhibition of p50/p65-mediated COX-2 promoter
activation.
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MODULATION OF CHONDROCYTE METABOLIC PATHWAYS BY NSAIDS
AND THE CYCLOOXYGENASE-INHIBITING NITRIC OXIDE DONATOR
(CINOD) NCX 429
L. Maneix1, D. Ollitrault1, N. Bigot1, E. Duval1, M. Bolla2, S. Viappiani2,
K. Boumediene1
1Univ. of Caen, Caen, France; 2Nic Ox SA, Sophia Antipolis, France
Purpose: Osteoarthritis (OA) progression is accompanied by a reduction
of extracellular matrix and increased catabolism of collagen ﬁbers and
glycosaminoglycans in joints. Cyclooxygenase-inhibiting nitric oxide dona-
tors (CINODs) are novel anti-inﬂammatory compounds designed to provide
balanced COX-1 and COX-2 inhibition while releasing nitric oxide (NO),
an important modulator of vascular tone. In the cartilage, the role of
NO is controversial, as it is a recognized marker of inﬂammation and a
possible cause of chondrocyte loss, but also a potent immuno-modulating
factor improving joint vascular perfusion. We investigated the effects of the
CINOD NCX 429 and reference NSAIDs (naproxen and celecoxib) in stim-
ulated adult rabbit chondrocytes, focusing on their catabolic and anabolic
activities, as well as inﬂammatory parameters.
Methods: Primary cultures of adult rabbit (4-6 months) articular chondro-
cytes (RACs) were pre-incubated with test drugs (1-10 μM, 8 hours) before
addition of IL-1β (10 ng/ml, 16 additional hours) in 5% O2 conditions, to
mimic joint limited perfusion. Levels of mRNA were determined by quan-
titative RT-PCR for assessing expression of extracellular matrix proteins
(aggrecan and collagen type II) and matrix proteases [aggrecanases and
matrix metalloproteases (MMPs)]. NO production was determined by mea-
surement of nitrite/nitrate (NOx) using the Griess method. Type II collagen
production was evaluated in the supernatant by Western blot analysis. To
assess COX inhibition, prostaglandin E2 (PGE2) was measured by enzyme
immunoassay in the supernatant of IL-1β stimulated chondrocytes (from 2
months-old rabbits) incubated with NCX 429 (1-100 μM).
Results: NCX 429 and naproxen did not show any impact on RAC viability.
In IL-1β-stimulated RACs, NCX 429 induced a 2-fold increase in type II col-
lagen expression, similarly to naproxen and celecoxib. NCX 429 stimulated
type II collagen at both mRNA and protein levels. In addition, NCX 429 re-
duced IL-1β-stimulated expression of MMP-1 by ∼ 50% and aggrecanase-1
and 2 expression (by ∼ 50% and 40%, respectively), with similar eﬃcacy
to naproxen and celecoxib. Conversely, IL-1β-induced increase in MMP-3
and decrease in aggrecan expression were not prevented by NCX 429 or
naproxen, whereas celecoxib inhibited MMP-3 expression by 40%. Inter-
estingly, while naproxen and celecoxib increased IL-1β-stimulated NOx
levels by ∼ 50 and 30%, respectively, NCX 429 decreased NOx levels (by
∼ 25%). Finally, NCX 429 inhibited IL-1β-induced PGE2 biosynthesis in a
concentration-dependent manner, indicating effective COX inhibition.
Conclusions: NCX 429, naproxen and celecoxib modulate IL-1β-induced
expression of catabolic and anabolic markers in stimulated adult rabbit
articular chondrocytes. Interestingly, the CINOD NCX 429 slightly reduces
IL-1β-induced increase of endogenous NO synthesis, differently from the
other NSAIDs, likely by inhibiting inducible nitric oxide synthase (iNOS)
expression, as already reported for other CINODs. NO has been considered
as potentially detrimental for chondrocytes; however, donation of low
concentrations of NO from the CINOD NCX 429 does not seem to affect
chondrocyte survival or to increase the expression of mediators involved
in cartilage degeneration. CINODs may even inhibit endogenous overpro-
duction of NO, and therefore may represent an interesting therapeutic
approach for the treatment of osteoarthritis.
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EFFECTS OF RIBONUCLEINATE COMPONENTS OF OSTEOCHONDRINR S
OSTEOARTHRITIS THERAPY ON FORMATION AND ACTIVITY OF HUMAN
OSTEOCLASTS IN VITRO
M. Cantley1, D.R. Haynes1, K.D. Rainsford2
1Univ. of Adelaide, Adelaide, Australia; 2Sheﬃeld Hallam Univ., Sheﬃeld,
United Kingdom
Purpose: To establish if the ribonucleinate components of the osteo-
arthritis natural drug, Osteochondrin® S (OST) affect the bone-resorbing
functions and gene expression in osteoclasts.
Methods: Human osteoclasts were generated in vitro from culture of
RANKL-M-CSF stimulated peripheral blood mononuclear cells for 17d. Cells
were treated with 23.5-587.2 ng/mL OST or 0.2-5 mg/mL RNA components
of connective tissues or yeast (as used to make OST) and their effects on
osteoclast formation were assessed using a Tartrate-Resistant Acid Phos-
phatase (TRAP) stain. Cell were also grown on dentine slices and used to
determine the effects on osteoclast bone resorption was The pit formation
on dentine was determined by scanning electron microscopy. In separate
experiments, real time PCR was used to determine mRNA expression of
principal enzymes or signalling molecules governing osteoclast functions.
Results: OST and its RNA components showed approximately equiva-
lent concentration-dependent inhibition of TRAP stained osteoclasts and
associated reduction in pit formation on dentine (Fig. 1A–F).
OST was, however, more potent in preventing bone resorption than the
individual RNAs. mRNA expression of calcitonin receptor (CTR) was reduced
Figure 1A–F: Effects of OST and RNA components on osteoclast-mediated bone resorp-
tion. Statistical signiﬁcance (***p<0.001; *p<0.05) - one-way ANOVA.
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while Tumour Necrosis-α-like Weak inducer of Apoptosis (TWEAK) and
interferon-β were increased over17d. No changes occurred in expression of
mRNA for RANK, NFATc1, OSCAR or cathepsin-K.
Conclusions: The results show that bone resorption is inhibited by OST
and its component RNAs in a concentrated-related manner. The inhibitory
effects may possibly relate to events downstream of NFATc1 regulation.
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THE CINOD NCX 429 EXERTS ANTI-INFLAMMATORY EFFECTS IN ISOLATED
HUMANMONOCYTES AND MACROPHAGES
A. Amoruso1, D. Federici Canova1, L.G. Fresu1, J. Padron2, E. Ongini2,
S. Brunelleschi1
1Dept Med. Sci., Univ. of Piemonte Orientale "A. Avogadro", Novara, Italy;
2Nicox Res. Inst., Bresso, Milan, Italy
Purpose: Cyclooxygenase-inhibiting nitric oxide donators (CINODs) repre-
sent a new class of anti-inﬂammatory drugs designed to provide the anti-
inﬂammatory effects of non steroidal anti-inﬂammatory drugs (NSAIDs)
while donating nitric oxide (NO) with the aim of mitigating side-effects
in the gastrointestinal and cardiovascular systems. CINODs exercise their
analgesic and anti-inﬂammatory effects via cyclooxygenase (COX) inhibi-
tion, and exhibit an improved tolerability, via the protective action of nitric
oxide (NO) on gastric mucosa and vascular function. We have assessed the
effect of NCX 429, a naproxen-based CINOD, on human monocytes and
monocyte-derived macrophages (MDM) isolated from healthy volunteers,
in comparison with naproxen.
Methods: Human monocytes were isolated from heparinised venous blood
of healthy donors by standard techniques in Hystopaque gradient centrifu-
gation (400×g, 30 min, room temperature) and recovered by thin suction
at the interface. MDM were prepared from monocytes, by culture (8-10
days) in RPMI 1640 medium containing 20% FBS.
Cells (1×106) were pre-treated for 1 h with NCX 429 or naproxen (1 nM
- 100 μM) and then stimulated with 0.1 μM phorbol myristate acetate
(PMA) for 24 h. Supernatant was collected at the end of the incubation for
measurement of IL-6 release (ELISA).
To evaluate superoxide anion (O–2) production, human monocytes (1×106
cells/plate) were stimulated with PMA (1 μM, 30 min) in the absence
or presence of NCX 429 or naproxen. O–2 production was evaluated by
the superoxide dismutase (SOD)-inhibitable cytochrome C reduction and
expressed as nmol cytochrome C reduced/106 cells/30 min. The MMP-9
activity was evaluated by gelatin zymography.
Results: NCX 429 in the range 1 nM - 100 μM inhibited PMA-induced IL-6
release in monocytes in a concentration dependent mode (IC50 = 870 nM);
at the maximal concentration, the inhibition by NCX 429 reached 62±8%,
signiﬁcantly higher than the inhibition afforded by naproxen (36±4%,
p<0.05, n=7). In MDM, 100 μM NCX 429 inhibited by 52±11% (n=5) PMA-
induced IL-6 release, while naproxen had no effect. A stronger effect of NCX
429 was also observed by evaluating superoxide production in monocytes
and MDM. At 1 μM, NCX 429 inhibited PMA-induced O–2 production by
about 24% in monocytes and 60% in MDM (n =6), whereas naproxen
produced little or no effect. Moreover, NCX 429 reduced PMA-induced O–2
production in monocytes isolated from patients affected by rheumatoid
arthritis (n=3). Interestingly, NCX 429, but not naproxen, signiﬁcantly
inhibited matrix metalloproteinase (MMP)-9 activity in lipopolysaccharide
(LPS)-challenged monocytes from healthy volunteers (p<0.05 vs LPS, n=3).
Conclusions: These results show additional anti-inﬂammatory effects of
NCX 429 with respect to the reference NSAID, naproxen. CINODs, through
NO donation, have been shown to have a favourable blood pressure and
gastrointestinal proﬁle relative to available NSAIDs in animal models; the
present data suggest that NO donation from CINODs might also account
for further anti-inﬂammatory effects beside the ones dependent on COX
inhibition.
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NAPROXCINOD, UNLIKE NAPROXEN, INHIBITS EXPRESSION OF iNOS IN
ACTIVATED MACROPHAGES IN VITRO
D. Ronchetti, E. Bastia, D. Miglietta, J. Padron
Nicox Res. Inst. Srl, Bresso, Milan, Italy
Purpose: Macrophages play a pivotal role in several inﬂammatory diseases
and represent a valuable model for studying anti-inﬂammatory proper-
ties of new drugs. Activated macrophages produce and release numerous
inﬂammatory mediators including cytokines, prostaglandins and reactive
oxygen and nitrogen species. At physiologic concentrations, nitric oxide
(NO) inhibits the expression and activity of pro-inﬂammatory mediators,
whereas at high concentrations (i.e., during inﬂammation) it induces cy-
tokine expression and tissue damage. Naproxcinod is the ﬁrst-in-class
cyclooxygenase inhibiting nitric oxide donator (CINOD), designed to exert
effective anti-inﬂammatory actions through cyclooxygenase (COX) inhibi-
tion while releasing NO, with the aim of mitigating NSAIDs-associated
unwanted effects. The purpose of this study was to characterize COX-
inhibiting and NO-donating properties of the CINODs naproxcinod and NCX
429, and to investigate whether they modulate the expression of inducible
nitric oxide synthase (iNOS) in activated macrophages differently from a
reference NSAID, naproxen.
Methods: NO release was evaluated by assessing vascular tone on isolated
rabbit aortic rings pre-contracted with methoxamine (3 μM) was recorded
after incubation with vehicle or test compounds (0.01-100 μM) in the
presence or absence of the soluble guanylyl cyclase (sCG) inhibitor ODQ
(1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, 10 μM).
To assess COX-1 inhibition, RAW 264.7 murine macrophages were incu-
bated with test compounds (0.01-100 μM, 30 minutes) and stimulated
with arachidonic acid (1 μM, 15 min). To assess COX-2 inhibition, aspirin
(100 μM) pretreated cells were incubated with 1 μg/ml LPS and 10 ng/ml
IFNγ.for 16 h to induce COX-2 expression and then treated as above. Es-
terases (1.67 U/sample) were added to accelerate naproxcinod metabolism.
Supernatant was collected for enzymatic immuno-assay of PGE2.
In different experiments, cells were incubated overnight with LPS (1 μg/ml)
and IFNγ (10ng/ml) in the presence of vehicle or test compounds (0.1-100
μM) and nitrites quantiﬁed in the supernatant by the Griess reaction. Cells
were lysed for Western blot and iNOS quantiﬁed by chemiluminescence.
Results: Naproxcinod and naproxen showed similar in vitro inhibition of
COX-1 and COX-2 (COX-1 IC50= 3.0±1.3 and 8.1±5.8 μM, respectively;
COX-2 IC50= 3.9±1.7 and 10.4±8.4 μM, respectively). Additionally, naprox-
cinod and NCX 429, but not naproxen, were able to induce relaxation of
pre-contracted rabbit aortas (EC50=5.5±1.7 and 6.2±1.6 μM, respectively),
similarly to isosorbidemononitrate (EC50=10.8±2.4 μM). The vasorelaxation
was mediated by activation of the NO-signaling pathway, as prevented by
the sGC inhibitor ODQ.
Interestingly, in activated RAW 264.7 macrophages, naproxcinod and NCX
429 (IC50=0.8μM) but not naproxen inhibited LPS/IFNγ-mediated increase
in nitrite concentrations. Consistently, naproxcinod reduced iNOS protein
expression, whereas naproxen was ineffective.
Conclusions: The CINODs naproxcinod and NCX 429 inhibit expression
of iNOS in activated macrophages in vitro, likely through a mechanism
involving donation of NO. Therefore, in addition to the reported differenti-
ated blood pressure and gastrointestinal proﬁle over available NSAIDs, NO
release from CINODs might confer additional anti-inﬂammatory properties.
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KNEE OSTEOARTHRITIS: SAFETY AND EFFICACY OF CLODRONATE IV
M. Scarpellini, A. Lurati, M. Marrazza, K. Re, D. Bompane
Magenta Hosp., Magenta, Italy
Purpose: To assess the clinical effects of intravenous courses of clodronate
in established knee osteoarthritis (OA) resistant to common treatment with
non-steroidal anti-inﬂammatory drugs or local corticosteroids
Methods: Subjects aged 40 to 80 years with knee OA, from moderate to
severe, were enrolled. The patients were treated with a 10 days course
of clodronate i.v. 300mg/die every 3-6 months for 1 year. Patients were
followed-up every 3 months. At each visit, pain scores (100 mm visual
analogue scale [VAS]), Lequesne index scores, NSAID intake, physician and
patient global assessments scores were recorded. Adverse events (AEs)
were recorded throughout the study.
Results: 122 patients (females 107, males 15; mean age 74.3±5.1, Kellgren-
Lawrence grade II or III OA) were enrolled. Statistically signiﬁcant re-
ductions in VAS pain scores, Lequesne index scores and NSAID usage
were reported at all time-points (baseline VAS 67.02±10.4, 1 month VAS
46.5±15.3, 6 months VAS 41.7±11.3, 12 months 37.2±4.3 p<0.01). No
systemic, serious or severe side effects were observed.
Conclusions: This study supports the safety, tolerability and effectiveness
of Clodronate in the treatment of symptomatic knee OA. Clodronate may
also offer economic beneﬁts due to a reduction in NSAID usage and the
resultant reduction in management costs of NSAID related side-effects. This
